Form 4: Connect Biopharma Holdings Director Receives Stock Grant
Insider Transaction (Form 4)
Kleanthis Gabriel Xanthopoulos, a Director of Connect Biopharma Holdings Ltd, received 5,000 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 5,000 Ordinary Shares on September 30, 2026; holds 91,554 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kleanthis Gabriel Xanthopoulos — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Ordinary Shares | 5,000 | — | — | 91,554 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (5,000 shares) |
Keywords
insider transaction, Form 4, CNTB, Connect Biopharma Holdings Ltd, neutral, Kleanthis Gabriel Xanthopoulos
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.